Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > January 23, 2023
Daily News
January 23, 2023
- Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
- First Abortion Pill Candidate in Japan Up for Panel Review on Jan. 27
January 23, 2023
- US FDA Lifts Clinical Hold of Astellas’ Pompe Gene Therapy
January 23, 2023
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
January 23, 2023
- PMDA Reviewing Safety Risks for GLP-1 Agents
January 23, 2023
- Acoalan’s PIII Trial for Preeclampsia Due to Complete in July: Kyowa Kirin
January 23, 2023
- Meiji’s Stelara Biosimilar Shows Therapeutic Equivalence; Filing Eyed in 2023
January 23, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…